Edesa Biotech Reports Fiscal First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2020 and provided an update on its business.
Earlier this month, the company announced that it has been awarded a C$14 million reimbursement grant from the Canadian government. The funds will support the Phase 2 portion of an ongoing Phase 2/Phase 3 clinical study of Edesa s investigational drug, EB05, as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Should the antibody treatment demonstrate promising results at the Phase 2 readout, the company plans to continue with a pivotal Phase 3 study and enter negotiations for additional government funding. Last mont
Edesa Biotech Receives C$14 million for COVID-19 Study saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Private Debt Partners Appoints Six New Members to Advisory Board
News provided by
Share this article
Share this article
TORONTO and MONTREAL, Jan. 27, 2021 /CNW/ - Private Debt Partners ( PDP or the Company ) is pleased to announce the nominations of Mr. Mario Charpentier, Mr. Daniel Gallivan, Mr. Paul Hill, Mr. Richard Kanemy, Ms. Kristi Miller and Dr. Par Nijhawan, to its Advisory Board. The newly appointed Advisory Board members bring diverse finance, banking, legal, operational, governance and leadership experience that will complement and enhance PDP s core competencies as the Company deploys its Senior Direct Lending Fund and its Senior Opportunities Fund, which are focused on lending capital to high-quality Canadian mid-market businesses.
Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
TORONTO, ON / ACCESSWIRE / January 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases.
Dr. Par Nijhawan, Chief Executive Officer of Edesa, said that physicians involved in the company s ARDS study identified a number of COVID-19 patients who they believed could benefit from the experimental treatment, but were too ill to be considered for the main study. This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering
(EDSA), (VIR) - Why Vir, Edesa Biotech Shares Are Ripping Higher Today benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.